Shots:
- Transcarent to acquire Accolade with a total equity value of ~$621M, with shareholders receiving $7.03/share in cash, making Accolade private. Closing expected in Q2’25
- The acquisition will yield a unified platform with Transcarent’s WayFinding (generative AI), pharmacy benefits & overall care experiences (incl. weight health, cancer & surgery care) & Accolade’s data of advocacy, EMO, & primary care
- The platform will offer custom & superior services at lower cost, plus a broad local database for its members while reducing physician workload by easier access & less paperwork, leveraging the benefits of both company’s platforms
Ref: Accolade | Image: Accolade
Related News:- Boston Scientific Reports the Acquisition of Silk Road Medical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
